Key result
Black cancer patients face ~3x higher risk of cancer-associated thrombosis compared to White patients.
Why the study?
Studies demonstrate a need to advance understanding of both the biologic and sociologic underpinnings of observed racial and ethnic differences in cancer-associated thrombosis risk.
Significant racial and ethnic disparities exist in the incidence, mortality, and treatment of cancer-associated thrombosis, highlighting the need to address both biologic and sociologic determinants of health.
Racial disparities may warrant consideration in cancer VTE risk models; leaves open validation of biologic and sociologic drivers in prospective studies.
Active malignancy increases the risk of developing venous thromboembolism (VTE) by four- to seven-fold. The risk of VTE, including deep vein thrombosis and pulmonary embolism, in patients with cancer varies based on several clinical factors, such as cancer stage and age. However, race and ethnicity are also associated with increased VTE risk. Black (African American) patients with cancer have a higher risk of developing VTE than White patients, while Asian/Pacific Islanders have a lower risk. Studies on cancer-associated thrombosis demonstrate a need to advance our understanding of both the biologic and sociologic underpinnings of the observed differences according to race. Addressing the causes of these disparities can better health outcomes for historically underserved patient populations.
No takes yet. Share an insight, caveat, or question.
Wiredu et al. (2021) conducted a review in Cancer-Associated Thrombosis. Black patients with cancer are three times more likely to develop cancer-associated thrombosis compared to White patients, while Asian/Pacific Islanders have a lower risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: